ArticleHealth economics2021
Flexible Bayesian longitudinal models for cost-effectiveness analyses with informative missing data.
Article in Health economics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Missing Data in Trial-Based Cost-Effectiveness Analysis: The Journey Continues.PharmacoEconomics · 2026Review
- The handling of missing data in trial-based economic evaluations: should data be multiply imputed prior to longitudinal linear mixed-model analyses?The European journal of health economics : HEPAC : health economics in prevention and care · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Cost-effectiveness analyses (CEA) are recommended to include sensitivity analyses which make a range of contextually plausible assumptions about missing data. However, with longitudinal data on, for example, patients' health-related quality of life (HRQoL), the missingness patterns can be complicated because data are often missing both at specific timepoints (interim missingness) and following loss to follow-up. Methods to handle these complex missing data patterns have not been developed for CEA, and must recognize that data may be missing not at random, while accommodating both the correlation between costs and health outcomes and the non-normal distribution of these endpoints. We develop flexible Bayesian longitudinal models that allow the impact of interim missingness and loss to follow-up to be disentangled. This modeling framework enables studies to undertake sensitivity analyses according to various contextually plausible missing data mechanisms, jointly model costs and outcomes using appropriate distributions, and recognize the correlation among these endpoints over time. We exemplify these models in the REFLUX study in which 52% of participants had HRQoL data missing for at least one timepoint over the 5-year follow-up period. We provide guidance for sensitivity analyses and accompanying code to help future studies handle these complex forms of missing data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.